Conference Coverage

Cancer risk tied to some manufactured foods


 

FROM SABCS 2021

Trans fatty acid intakes and cancer risk

Investigating associations between trans fatty acid intake (total ruminant [rTFAs], industrial [iTFAs], and corresponding specific isomers and cancer risk), the analysis of Gaëlle Wendeu-Foyet, PhD, Sorbonne Paris Nord University, found a total of 3,374 incident cancer cases (982 breast, 405 prostate) in an overall population of 104,909. Dietary intake of total TFAs was associated with higher prostate cancer risk (hazard ration for quartile 4 versus 1: 1.27, 1.11-1.77 P-trend = 0.005). Also, rTFAs were associated with increased overall cancer risk (1.16, 1.02-1.32 P-trend = 0.07), in particular the conjugated linoleic acid isomers (CLA) (1.19, 1.04-1.36 P-trend = 0.04). These associations were specifically observed for breast cancer (rTFAs: 1.35, 1.06-1.72 P-trend = 0.01; CLA: 1.29, 1.00-1.66 P-trend = 0.048), in particular before menopause (rTFAs: 1.68, 1.06-2.67 P-trend = 0.02; CLA: 2.013, 1.25-3.23 P-trend = 0.003). Several iTFAs were associated with overall (1.18, 1.06-1.31 P-trend = 0.02 for transdocosenoic acid), breast (isomer 18:2t: 1.30, 1.06-1.58 P-trend = 0.01; hexadecenoic acid: 1.28, 1.05-1.56 P-trend = 0.02) and prostate (transdocosenoic acid: 1.52, 1.09-2.12 P-trend = 0.07) cancer risks.

“These results support the WHO’s goal of achieving elimination from food supplies of industrially produced TFAs,” Dr. Foyet said. “The consumption of food products containing partially hydrogenated oils should be avoided.”

Nutrition, along with avoiding tobacco intake, is one of the main modifiable risk factors for chronic diseases. “There is a lot at stake in terms of prevention. This requires a combination of actions at the individual level to the public level by informing the public through food labeling,” Ms. Debras said.

It also requires influencing the context in which citizens evolve by encouraging manufacturers to improve their products (pricing policies, commitment charters for product reformulation, etc.), and limiting advertising and marketing for products of poor nutritional quality (especially among children),” she said.

Pages

Recommended Reading

Ongoing HER2 breast cancer therapy may cost an additional $68,000 per patient
MDedge Hematology and Oncology
‘Surprising’ lack of benefit to adding palbociclib to endocrine therapy in early HR+/HER2– breast cancer
MDedge Hematology and Oncology
Women struggle with benzodiazepine addiction post chemotherapy treatment
MDedge Hematology and Oncology
Omega-3 supplements may impact breast cancer risk
MDedge Hematology and Oncology
Antibiotic use associated with triple-negative breast cancer mortality
MDedge Hematology and Oncology
Pembrolizumab improves event-free survival in early TNBC
MDedge Hematology and Oncology
PD-L1 cutoff for pembrolizumab in mTNBC confirmed
MDedge Hematology and Oncology
Sacituzumab govitecan effective in Black mTNBC patients
MDedge Hematology and Oncology
More evidence ties some antipsychotics to increased breast cancer risk
MDedge Hematology and Oncology
Breast cancer-related musculoskeletal pain alleviated with acupuncture
MDedge Hematology and Oncology